Deciphera Pharmaceuticals (DCPH) Now Covered by Analysts at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report released on Wednesday, MarketBeat.com reports. The firm issued an overweight rating and a $53.00 price target on the stock.
Other research analysts also recently issued reports about the company. B. Riley cut their price target on Deciphera Pharmaceuticals from $52.00 to $43.00 and set a buy rating on the stock in a report on Wednesday, May 9th. BidaskClub downgraded Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Friday, July 13th. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $41.00 price target on the stock in a report on Tuesday, July 24th. Canaccord Genuity assumed coverage on Deciphera Pharmaceuticals in a report on Tuesday, August 7th. They issued a buy rating and a $55.00 price target on the stock. Finally, ValuEngine upgraded Deciphera Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $50.44.
DCPH opened at $35.47 on Wednesday. Deciphera Pharmaceuticals has a 52 week low of $15.15 and a 52 week high of $45.61. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44.
A number of hedge funds have recently made changes to their positions in DCPH. Redmile Group LLC grew its stake in Deciphera Pharmaceuticals by 79.9% during the 2nd quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after buying an additional 655,800 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Deciphera Pharmaceuticals during the 2nd quarter worth $21,989,000. Orbimed Advisors LLC grew its stake in Deciphera Pharmaceuticals by 30.8% during the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after buying an additional 472,800 shares during the last quarter. Opaleye Management Inc. purchased a new position in Deciphera Pharmaceuticals during the 1st quarter worth $7,314,000. Finally, BlackRock Inc. grew its stake in Deciphera Pharmaceuticals by 3,989.6% during the 4th quarter. BlackRock Inc. now owns 363,483 shares of the company’s stock worth $8,241,000 after buying an additional 354,595 shares during the last quarter. Hedge funds and other institutional investors own 47.73% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.